# RenX Enterprises Corp.: overview RENX · Nasdaq · CIK 1959023 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/renx.md) · [Financials](/companies/renx/financials.md) · [Filings](/companies/renx/filings.md) · [Insiders](/companies/renx/insiders.md) Latest reported revenue: [$4.3m](/filings/0001213900-26-089068.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089068). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [81.2](/filings/0001213900-25-110837.md) | [34.4 d](/filings/0001213900-26-037999.md) | [18.2](/filings/0001213900-26-057186.md) | [1,403](/filings/0001213900-26-089068.md) | [3,516](/filings/0001213900-25-110837.md) | [3,284 d](/filings/0001213900-26-037999.md) | [3,958](/filings/0001213900-26-057186.md) | [4,256](/filings/0001213900-26-089068.md) | | Gross margin | % | [100.0%](/filings/0001213900-25-110837.md) | [(431.5%) d](/filings/0001213900-26-037999.md) | [35.1%](/filings/0001213900-26-057186.md) | [38.9%](/filings/0001213900-26-089068.md) | [25.8%](/filings/0001213900-25-110837.md) | [28.4% d](/filings/0001213900-26-037999.md) | [33.7%](/filings/0001213900-26-057186.md) | [31.9%](/filings/0001213900-26-089068.md) | | Operating margin | % | [(1712.6%)](/filings/0001213900-25-110837.md) | [(5131.8%) d](/filings/0001213900-26-037999.md) | [(6955.8%)](/filings/0001213900-26-057186.md) | [(351.8%)](/filings/0001213900-26-089068.md) | [(66.3%)](/filings/0001213900-25-110837.md) | [(119.4%) d](/filings/0001213900-26-037999.md) | [(70.0%)](/filings/0001213900-26-057186.md) | [(70.4%)](/filings/0001213900-26-089068.md) | | Net margin | % | [(2883.9%)](/filings/0001213900-25-110837.md) | [(4452.4%) d](/filings/0001213900-26-037999.md) | [(11997.8%)](/filings/0001213900-26-057186.md) | [(408.1%)](/filings/0001213900-26-089068.md) | [(123.7%)](/filings/0001213900-25-110837.md) | [(112.8%) d](/filings/0001213900-26-037999.md) | [(235.7%)](/filings/0001213900-26-057186.md) | [(188.4%)](/filings/0001213900-26-089068.md) | | Diluted EPS | $ per share | [(2.61)](/filings/0001213900-25-110837.md) | not reported | [(21.68)](/filings/0001213900-26-057186.md) | [(45.90)](/filings/0001213900-26-089068.md) | [(1.12)](/filings/0001213900-25-110837.md) | not reported | [(4.87)](/filings/0001213900-26-057186.md) | [(3.08)](/filings/0001213900-26-089068.md) | | Free cash flow | $k | [(275) d](/filings/0001213900-24-098505.md) | [(1,058) d](/filings/0001213900-25-026215.md) | not reported | not reported | not reported | not reported | [(2,550)](/filings/0001213900-26-057186.md) | [(4,301) d](/filings/0001213900-26-089068.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.2](/filings/0001213900-26-037999.md) | [8.2](/filings/0001213900-26-037999.md) | | Gross margin | % | not reported | not reported | [12.0%](/filings/0001213900-26-037999.md) | [29.1%](/filings/0001213900-26-037999.md) | | Operating margin | % | not reported | not reported | [(3160.1%)](/filings/0001213900-26-037999.md) | [(151.5%)](/filings/0001213900-26-037999.md) | | Net margin | % | not reported | not reported | [(4292.2%)](/filings/0001213900-26-037999.md) | [(194.1%)](/filings/0001213900-26-037999.md) | | Diluted EPS | $ per share | [(2444.26)](/filings/0001213900-24-028274.md) | [(28.65)](/filings/0001213900-25-026215.md) | [(195.69)](/filings/0001213900-26-037999.md) | [(83.99)](/filings/0001213900-26-037999.md) | | Free cash flow | $m | not reported | [(4.6)](/filings/0001213900-25-026215.md) | [(2.6)](/filings/0001213900-25-026215.md) | [(10.9)](/filings/0001213900-26-037999.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/renx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $50.1k | 26,647 | | Added +6,684 | | [Steward Partners Investment Advisory, LLC](/funds/1723397.md) | 2026-06-30 | $47.0k | 25,000 | | New +25,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $25.4k | 13,512 | | New +13,512 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $24.8k | 13,182 | | New +13,182 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $11.4k | 6,067 | | New +6,067 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.3k | 2,306 | | Added +1,737 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $929 | 494 | | New +494 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $126 | 67 | | Unchanged | | [Blue Trust, Inc.](/funds/1856022.md) | 2026-06-30 | $66 | 35 | | Unchanged | | [Virtu Financial LLC](/funds/1533964.md) | 2026-06-30 | $25 | 13,246 | | New +13,246 | ## Recent filings [All 286 filings](/companies/renx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 21:15 ET | [8-K](/filings/0001213900-26-106886.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-26-106886 | | 2026-08-28 | 21:15 ET | [8-K](/filings/0001213900-26-095188.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-095188 | | 2026-08-21 | 20:01 ET | [8-K](/filings/0001213900-26-092589.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-092589 | | 2026-08-13 | 20:02 ET | [10-Q](/filings/0001213900-26-089068.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089068 | | 2026-08-13 | 13:00 ET | [8-K](/filings/0001213900-26-088753.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-088753 | | 2026-07-07 | 20:16 ET | [8-K](/filings/0001213900-26-075956.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-075956 | | 2026-06-15 | 21:00 ET | [8-K](/filings/0001213900-26-068872.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-068872 | | 2026-05-15 | 21:01 ET | [DEF 14A](/filings/0001213900-26-057927.md) | Proxy statement, period 2026-06-12 | 0001213900-26-057927 | | 2026-05-15 | 13:01 ET | [10-Q](/filings/0001213900-26-057186.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057186 | | 2026-05-15 | 12:00 ET | [8-K](/filings/0001213900-26-057151.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-057151 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037999.md), filed Apr 1, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e05b9b89-94de-4de0-ad55-8035ab37295f) ## About the filer - CIK: 1959023 - Tickers: RENX - Exchange: Nasdaq - SIC code: 4953 Refuse Systems - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.